HER2-Negative Breast Cancer Terminated Phase 2 Trials for Pegfilgrastim (DB00019)

IndicationStatusPhase
DBCOND0072181 (HER2-Negative Breast Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00679029Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast CancerTreatment